Literature DB >> 29673774

Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen.

Ho-Jin Kim1, Jeong-Wan Seo1, Mee-Sook Roh2, Ji-Hyun Lee3, Ki-Hoon Song4.   

Abstract

BACKGROUND: Nodal melanocytic nevi (NNs) encountered during sentinel lymph node biopsy (SLB) for malignant melanoma are usually difficult to distinguish from metastatic melanoma. However, NNs have not been well studied in acral lentiginous melanoma (ALM) in Asian populations.
OBJECTIVE: To investigate the clinical characteristics and significance of NNs in SLB specimens from patients with ALM.
METHODS: We retrospectively analyzed 84 patients with ALM who underwent SLB between June 2010 and July 2017.
RESULTS: Of the 84 patients with ALM, 9 (10.7%) had NNs in their SLB specimens. NNs were significantly more common in SLB specimens than in specimens not obtained by SLB. The presence of pre-existing melanocytic lesions was found to be associated with NNs (P < .001). The 5-year overall survival was significantly higher in patients with ALM with NNs than in patients with a positive SLB result (P = .047). Distant recurrence in patients with ALM with NNs was significantly lower than in patients a positive SLB result (P = .03). LIMITATIONS: The small sample size, single-center study design, and retrospective nature of the study were the limitations.
CONCLUSION: In Asian populations, the prevalence of NNs in ALM is similar to that reported in Europe and the United States. The rates of distant recurrence and overall survival in patients with ALM who have NNs are similar to those of patients who do not have metastatic melanoma.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-year overall survival; Asia; acral lentiginous melanoma; metastatic melanoma; nodal melanocytic nevi; sentinel lymph node biopsy

Mesh:

Year:  2018        PMID: 29673774     DOI: 10.1016/j.jaad.2018.04.016

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  Genetic investigation of nodal melanocytic nevi in cases of giant congenital melanocytic nevus.

Authors:  Y Cao; X Yang; Y-M Lai; L Jia; X-T Diao; Q Zhuang; D-M Lin
Journal:  Histol Histopathol       Date:  2020-07-30       Impact factor: 2.303

2.  Intra-nodal nevi in sentinel node-negative patients with cutaneous melanoma does not influence survival.

Authors:  F S A de Beer; P J van Diest; V Sigurdsson; M El Sharouni
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-10-17       Impact factor: 6.166

3.  The efficacy of 99mTc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients.

Authors:  Jiayong Liu; Zhichao Tan; Ruifeng Xue; Zhengfu Fan; Chujie Bai; Shu Li; Tian Gao; Lu Zhang; Zhiwei Fang; Lu Si
Journal:  Ann Transl Med       Date:  2022-01

4.  Long non-coding RNA expression identified by microarray analysis: Candidate biomarkers in human acral lentiginous melanoma.

Authors:  Hao-Ze Shi; Jing-Shu Xiong; Cong-Cong Xu; Wen-Bo Bu; Yan Wang; Jian-Fang Sun; Hao Chen
Journal:  Oncol Lett       Date:  2019-12-11       Impact factor: 2.967

5.  The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.

Authors:  Wei Sun; Yu Xu; JiLong Yang; ZhiChao Liao; Tao Li; Kai Huang; Poulam Patel; WangJun Yan; Yong Chen
Journal:  Cancer Commun (Lond)       Date:  2020-10-06

6.  Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma.

Authors:  Laura Susok; Thilo Gambichler
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-15       Impact factor: 4.553

7.  Melanocytic nevi in sentinel lymph nodes: association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas.

Authors:  Lutz Kretschmer; Viktor Schnabel; Christian Kromer; Christoph Bauer-Büntzel; Annika Richter; Felix Bremmer; Fabian Kück; Katharina Julius; Christina Mitteldorf; Michael P Schön
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-20       Impact factor: 4.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.